David P Fairlie
David P Fairlie
Bestätigte E-Mail-Adresse bei imb.uq.edu.au - Startseite
Zitiert von
Zitiert von
The future of peptide‐based drugs
DJ Craik, DP Fairlie, S Liras, D Price
Chemical Biology & Drug Design 81 (1), 136-147, 2013
Protease inhibitors: current status and future prospects
D Leung, G Abbenante, DP Fairlie
Journal of Medicinal Chemistry 43 (3), 305-341, 2000
Cu (II) potentiation of Alzheimer Aβ neurotoxicity: correlation with cell-free hydrogen peroxide production and metal reduction
X Huang, MP Cuajungco, CS Atwood, MA Hartshorn, JDA Tyndall, ...
Journal of Biological Chemistry 274 (52), 37111-37116, 1999
MR1 presents microbial vitamin B metabolites to MAIT cells
L Kjer-Nielsen, O Patel, AJ Corbett, J Le Nours, B Meehan, L Liu, M Bhati, ...
Nature 491 (7426), 717-723, 2012
Characterization of copper interactions with Alzheimer amyloid β peptides
CS Atwood, RC Scarpa, X Huang, RD Moir, WD Jones, DP Fairlie, ...
Journal of Neurochemistry 75 (3), 1219-1233, 2000
Aqueous dissolution of Alzheimer's disease Aβ amyloid deposits by biometal depletion
RA Cherny, JT Legg, CA McLean, DP Fairlie, X Huang, CS Atwood, ...
Journal of Biological Chemistry 274 (33), 23223-23228, 1999
Solution structure of amyloid β-peptide (1− 40) in a water−micelle environment. Is the membrane-spanning domain where we think it is?
M Coles, W Bicknell, AA Watson, DP Fairlie, DJ Craik
Biochemistry 37 (31), 11064-11077, 1998
T-cell activation by transitory neo-antigens derived from distinct microbial pathways
AJ Corbett, SBG Eckle, RW Birkinshaw, L Liu, O Patel, J Mahony, Z Chen, ...
Nature 509 (7500), 361-365, 2014
Proteases universally recognize beta strands in their active sites
JDA Tyndall, T Nall, DP Fairlie
Chemical Reviews 105 (3), 973-1000, 2005
Histone deacetylases as regulators of inflammation and immunity
MR Shakespear, MA Halili, KM Irvine, DP Fairlie, MJ Sweet
Trends in Immunology 32 (7), 335-343, 2011
Antigen-loaded MR1 tetramers define T cell receptor heterogeneity in mucosal-associated invariant T cells
R Reantragoon, AJ Corbett, IG Sakala, NA Gherardin, JB Furness, Z Chen, ...
Journal of Experimental Medicine 210 (11), 2305-2320, 2013
Function, structure and therapeutic potential of complement C5a receptors
PN Monk, AM Scola, P Madala, DP Fairlie
British Journal of Pharmacology 152 (4), 429-448, 2007
Protease inhibitors in the clinic
G Abbenante, DP Fairlie
Medicinal Chemistry 1 (1), 71-104, 2005
Structure, function and pathophysiology of protease activated receptors
MN Adams, R Ramachandran, MK Yau, JY Suen, DP Fairlie, ...
Pharmacology & Therapeutics 130 (3), 248-282, 2011
Activity of recombinant dengue 2 virus NS3 protease in the presence of a truncated NS2B co-factor, small peptide substrates, and inhibitors
D Leung, K Schroder, H White, NX Fang, MJ Stoermer, G Abbenante, ...
Journal of Biological Chemistry 276 (49), 45762-45771, 2001
Beta strand mimetics
WA Loughlin, JDA Tyndall, MP Glenn, DP Fairlie
Chemical Reviews 104 (12), 6085-6118, 2004
Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells
L Qiu, A Burgess, DP Fairlie, H Leonard, PG Parsons, BG Gabrielli
Molecular Biology of the Cell 11 (6), 2069-2083, 2000
Macrocyclic peptidomimetics-forcing peptides into bioactive conformations
DP Fairlie, G Abbenante, DR March
Current Medicinal Chemistry 2 (2), 654-686, 1995
Inflammatory lipid mediators in adipocyte function and obesity
A Iyer, DP Fairlie, JB Prins, BD Hammock, L Brown
Nature Reviews Endocrinology 6 (2), 71, 2010
Substrate specificity of recombinant dengue 2 virus NS2B-NS3 protease: Influence of natural and unnatural basic amino acids on hydrolysis of synthetic fluorescent substrates
IE Gouvea, MA Izidoro, WAS Judice, MHS Cezarin, G Caliendo, ...
Arch Biochem Biophys 457, 187-196, 2007
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20